Phytochemicals in Alzheimer disease: The development of clinical trials

Joseph Quinn, Jeffrey Kaye, Thomas Montine, Robert Stackman

Research output: Contribution to journalReview article

6 Scopus citations

Abstract

Polyphenolics and other phytochemicals may have a role in the prevention or treatment of Alzheimer disease. Targets of therapy in Alzheimer disease include neurotransmitter deficits, beta amyloid neurotoxicity, oxidative damage, and inflammation, to name a few. Challenges to the development of phytochemical and other neuroprotectant therapy in Alzheimer disease include the inability to measure pathology in living patients and the challenge of detecting modification of an indolent disease course. These challenges are partially surmounted by the use of animal models and of biomarkers of disease. This review describes currently available animal models and biomarkers and surveys clinical trials of phytochemical therapies that are recently completed or currently under way. Both animal studies and clinical trials of Ginkgo biloba are described, as well as a trial of Uncaria tomentosa that has not been previously reported.

Original languageEnglish (US)
Pages (from-to)64-73
Number of pages10
JournalPharmaceutical Biology
Volume42
Issue numberSUPPL.
DOIs
StatePublished - Dec 1 2004

Keywords

  • Alzheimer disease
  • Antioxidants
  • Oxidative stress
  • Polyphenolics

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology
  • Pharmaceutical Science
  • Drug Discovery
  • Complementary and alternative medicine

Fingerprint Dive into the research topics of 'Phytochemicals in Alzheimer disease: The development of clinical trials'. Together they form a unique fingerprint.

  • Cite this